Thiogenesis Therapeutics, Corp. filed its Annual on May 02, 2022 for the period ending Dec 31, 2021. In this report its auditor, Dale Matheson Carr-Hilton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 CAD | -.--% | -1.41% | -6.67% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.67% | 23.27M | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- TTI Stock
- News Thiogenesis Therapeutics, Corp.
- Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt